Doug Chung

Dr. Doug Chung


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
RFRicardo F. Frausto
Ricardo F. Frausto
DCDoug Chung
Doug Chung
PBPayton M. Boere
Payton M. Boere
VSVinay S. Swamy
Vinay S. Swamy
HDHuong Viet Nguyen Duong
Huong Viet Nguyen Duong
AAAnthony J. Aldave
Anthony J. Aldave
The zinc finger e-box binding homeobox 1 (ZEB1) transcription factor is a master regulator of the epithelial to mesenchymal transition (EMT), and of the reverse mesenchymal to epithelial transition (MET) processes. ZEB1 plays an integral role in mediating cell state transitions during cell lineage specification, wound healing and disease. EMT/MET are characterized by distinct changes in molecular and cellular phenotype that are generally context-independent. Posterior polymorphous corneal dystrophy (PPCD), associated with ZEB1 insufficiency, provides a new biological context in which to understand and evaluate the classic EMT/MET paradigm. PPCD is characterized by a cadherin-switch and transition to an epithelial-like transcriptomic and cellular phenotype, which we study in a cell-based model of PPCD generated using CRISPR-Cas9-mediated ZEB1 knockout in corneal endothelial cells (CEnCs). Transcriptomic and functional studies support the hypothesis that CEnC undergo a MET-like transition in PPCD, termed endothelial to epithelial transition (EnET), and lead to the conclusion that EnET may be considered a corollary to the classic EMT/MET paradigm.

31 August 2026 in Cornea
Verified
Journal Article
Closed access
AVAnshuman Verma
Anshuman Verma
SCSunita Chaurasia
Sunita Chaurasia
MSMohd Salman
Mohd Salman
SGSneha Pranahitha Gorenka
Sneha Pranahitha Gorenka
DMDilip K. Mishra
Dilip K. Mishra
MRMuralidhar Ramappa
Muralidhar Ramappa
Purpose: To describe the clinical, histopathological, and genetic characteristics of a posterior polymorphous corneal dystrophy-4 pedigree spanning 3 generations with a novel GRHL2 variant and to highlight intrafamilial clinical variability. Methods: Comprehensive ophthalmic examinations were performed on affected family members. Histopathological evaluation of proband's corneal tissue excised during penetrating keratoplasty was conducted using hematoxylin & eosin, periodic acid–Schiff, and cytokeratin stains. Genomic DNA was analyzed using Sanger sequencing of the promoter and coding regions of ZEB1, GRHL2 , and OVOL2 . Results: The proband and her sibling exhibited steep corneas with variable ground-glass haze, vesicular, and band-like endothelial changes. The mother and maternal grandfather showed milder endothelial vesicles and subtle posterior stromal haze, with the grandfather least affected. Histopathology showed posterior stromal thickening with edema, Descemet membrane reduplication, and thinning along with endothelial loss. Genetic analysis identified a novel heterozygous intronic GRHL2 variant (c.20 + 544G > C) segregating in all affected members, absent in 80 controls, and located in a known regulatory hotspot associated with ectopic GRHL2 expression. Conclusions: Intronic regulatory variants of GRHL2 can cause familial posterior polymorphous corneal dystrophy (PPCD) with marked phenotypic variability. This is the first report of the c.20 + 544G > C variant and the second implicating the same intronic position in PPCD, underscoring the diagnostic importance of this hotspot and the need to include regulatory regions in targeted genetic testing for PPCD.